ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Efficacy and Safety of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue.Endocrine · 2026Pooled it
- Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Efficacy and safety ofFrontiers in oncology · 2022Pooled it
- Efficacy and safety of peptide receptor radionuclide therapy in advanced foregut and hindgut neuroendocrine tumors: a real-world experience from a single institution.Annals of nuclear medicine · 2026Article
- Whole genome and exome sequencing of pancreatic neuroendocrine tumour to investigate PRRT response.Endocrine-related cancer · 2026Article
- Article
- Biological Sex Influences the Pharmacokinetics and Organ Dosimetry ofPharmaceuticals (Basel, Switzerland) · 2026Article
- The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors.Frontiers in endocrinology · 2026Article
- Expanding the therapeutic horizon ofNagoya journal of medical science · 2025Review
- Safety and efficacy of re-treatment with [European journal of nuclear medicine and molecular imaging · 2025Article
- Analysis of clinical factors associated with incomplete standard protocolJapanese journal of radiology · 2025Article
- Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2025Review
- Radiation exposure and protection advice after [EJNMMI research · 2024Article
- Advances in Radioligand Theranostics in Oncology.Molecular diagnosis & therapy · 2024Review
- Review
- Everolimus in pituitary tumor: a review of preclinical and clinical evidence.Frontiers in endocrinology · 2024Review
- Comparison of the relative diagnostic performance ofFrontiers in oncology · 2024Article
- Review
- Site-specific performance ofFrontiers in oncology · 2023Article
- Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea.Cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to assess the efficacy and safety of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.